What I Saw Evaluating Biotech Companies for Acquisition and Partnership

Before I started BridgeLine, I spent time on the other side of the table. At Spark Therapeutics/Roche and Sarepta Therapeutics, part of my job was evaluating external companies as potential acquisition targets and strategic partners. Across evaluations spanning every modality I work with today, I saw a consistent set of patterns in what separated the companies that moved forward from the ones that didn't.

This isn't a checklist. It's what I actually looked for, what actually killed deals, and what I wish every early-stage biotech founder understood about how evaluators think.

Strategic fit comes first. Everything else is conditional.

Before anyone on our team opened a data package, we asked one question: does this company's target, indication, and modality align with where our portfolio is going?

This sounds obvious, but the implication is important. A company with solid preclinical data in an indication we weren't pursuing was a pass, no matter how good the science was. Conversely, a company in a strategically important space got a much deeper look, even if the initial data was early.

The lesson for founders: understand the portfolio thesis of whoever you're talking to. If you don't know what indications, modalities, or platform capabilities they're prioritizing, you're pitching blind. Strategic fit is the gate. Everything else comes after.

Weak preclinical data was the most common deal killer.

Once a company cleared the strategic fit screen, the nonclinical data package was where most evaluations stalled. And the most common problem wasn't bad data. It was missing data.

Companies would show up with encouraging efficacy results but no toxicology. Or they had toxicology in one species but hadn't addressed biodistribution. Or they had run the right studies in principle, but the study designs had gaps: no dose-response relationship established, endpoints that didn't match what regulators would expect, observation periods that were too short to be meaningful.

The specific gap I saw most often, and the one that surprised me most, was around safety and toxicology. Companies would iterate on their product for months, come back with slightly improved efficacy data, and assume that was what we wanted to see. But what we actually needed was insight into the toxicity profile. Efficacy gets you in the door. Safety is what lets the deal move forward.

The companies that kept coming back without a real inflection point.

This was one of the most frustrating patterns. A company would present, we'd identify gaps, and they'd go away to generate more data. Six months or a year later, they'd come back. But instead of addressing the fundamental questions, they'd bring incremental updates: slight improvements in editing activity, another cohort at a similar dose, a modest improvement in expression levels.

These weren't inflection points. They were data updates. And the difference matters.

An inflection point changes the risk profile of your program. It answers a question that was previously open. A pivotal tox study with clean margins is an inflection point. A biodistribution study showing favorable tissue targeting is an inflection point. Running the same efficacy model with a 15% better result is not.

Evaluators are tracking your program against a set of open questions. Every time you come back, we're asking: which questions did they close? If the answer is none, interest decays. Which brings me to the most important lesson.

Time kills deals.

Of everything I learned evaluating companies, this is the single most important thing I'd want every founder to internalize: the window for any deal is finite, and it closes for reasons that have nothing to do with your science.

When a company takes too long between meaningful milestones, three things happen simultaneously. First, portfolio priorities shift. What the acquiring company needed six months ago may not be what they need today. Internal programs advance, strategy pivots, leadership changes. The indication you're targeting might move down their priority list for reasons you'll never know about.

Second, internal champions move on. Every deal has someone inside the acquiring organization who is advocating for it. That person has a limited amount of political capital and attention. If the deal stalls, they redirect their energy elsewhere, and you lose your advocate.

Third, competitors advance. The landscape doesn't pause while you generate data. If another company in your space hits a clinical milestone or publishes stronger preclinical data while you're still iterating, the competitive dynamics shift against you.

The practical takeaway: sequence your studies to hit value-inflection milestones at regular intervals. Don't go dark for 12 months. If you're in an active conversation with a potential partner or acquirer, have a roadmap that shows when the next meaningful data readout is coming and what question it answers.

Partnerships can end for reasons that have nothing to do with you.

This is the corollary to "time kills deals," and it applies after the deal closes too. Partner priorities change rapidly, sometimes for reasons that are entirely internal and have nothing to do with your program's performance. A leadership transition, a portfolio reprioritization, a budget reallocation, any of these can result in a partnership ending earlier than expected. I saw this happen, and when it does, the impact on the smaller company can be significant, sometimes forcing difficult decisions about entire programs or teams.

That's not a failure of the founders. It's the reality of how large organizations operate. Priorities shift. Strategies evolve. Programs that were central to a partner's thesis one year can become peripheral the next. No amount of good science or strong execution on your side can fully control for that.

What founders can do is think about contract structure with this reality in mind. Where possible, design agreements so your company captures meaningful value at each milestone, not just at the end. Think about how data, intellectual property, and decision rights are handled if the partnership ends early. The goal isn't to be adversarial. It's to make sure that the work your team does along the way leaves the company in a stronger position regardless of what happens with any single partnership.

Presentation quality was a poor predictor of program quality.

I saw this go both ways. Companies with polished decks and compelling narratives sometimes had thin data underneath. And companies with poorly organized presentations sometimes had genuinely strong programs buried in bad formatting.

The most memorable example was a company with clinical data. The presentation was rough, but once we had the opportunity to dig into the actual efficacy results, the data spoke for itself. Clinical efficacy will always trump a poor presentation when you have evaluators willing to look past the surface.

But here's the catch: not every evaluator will look past the surface. At the screening stage, where you're one of dozens of companies being reviewed, presentation matters because it determines whether you get the deeper look. The data has to be there, but it also has to be findable and interpretable by someone reviewing your materials in a few hours, not a few days.

The mismatch I saw most often was in gene therapy.

Gene therapy companies, more than any other modality I evaluated, tended to have the widest gap between confidence and actual data quality. Early efficacy data in gene therapy can be dramatic: a single dose produces measurable transgene expression, biomarkers improve, the animal model shows correction. That early signal creates enormous enthusiasm.

But gene therapy programs also carry some of the most complex manufacturing, safety, and durability challenges in drug development. Companies that were highly confident based on proof-of-concept efficacy often hadn't grappled with manufacturing consistency, the immunogenicity profile, toxicity risks, or durability of expression, particularly in programs targeting highly proliferative tissues where transgene persistence is far less predictable.

And critically, many had not seriously considered how pre-existing immunity to AAV capsids impacts program development. It affects a significant portion of the patient population, shapes clinical trial design, and is one of the most consequential variables in determining who can actually be treated. The science was real, but the path to IND was longer and more complicated than the founders appreciated.

What this means for founders.

The gap I saw most consistently wasn't scientific. It was strategic. Companies weren't running the wrong experiments. They were running them in the wrong order, missing the studies that would answer the questions evaluators actually care about, and underestimating how quickly a window can close.

Understanding how the other side of the table thinks doesn't require being on the other side of the table. But it does require someone in the room who has been there.

Timothy S. Luongo, PhD, MSTR

Founder of BridgeLine Translational Partners. Before starting BridgeLine, he designed and executed IND-enabling preclinical programs and evaluated companies for acquisition and partnership at Spark Therapeutics/Roche and Sarepta Therapeutics. BridgeLine helps early-stage biotech teams build preclinical strategies and diligence-ready narratives that hold up when the scrutiny comes.

Book a Strategy Call